Piramal Pharma is aiming to boost earnings over the next two to three years by focusing on rising demand for complex drugs, particularly targeted cancer therapies. Chairperson Nandini Piramal said the company expects stronger growth as global interest in advanced treatments increases, especially in high-value segments like antibody-drug conjugates (ADCs). The company Continue Reading
